Inductive Bio, a leader in leveraging machine learning (ML) to accelerate compound optimization for small molecule drug discovery, announces the publication of the approach and findings from their recent collaboration with Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers.
Inductive Bio emerged with $4.3M in a seed funding round co-led by a16z Bio + Health and Lux Capital, with participation from Character, Bessemer Venture Partners, Alleycorp, and others. Inductive's team has deep expertise building innovative ML products and bringing drugs into the clinic.